CBG/CBD Oil for Chemotherapy-Induced Peripheral Neuropathy
Status:
NOT_YET_RECRUITING
Trial end date:
2028-02-28
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to learn if a commercially available cannabigerol (CBG)/cannabidiol (CBD) oil is safe, feasible to use, and can help reduce symptoms of chemotherapy-induced peripheral neuropathy (CIPN) in adults who have completed platinum-based chemotherapy for gastrointestinal cancers. The main questions it aims to answer are:
Is CBG/CBD oil safe and well-tolerated over a 12-week treatment period?
Can participants with CIPN use CBG/CBD oil consistently as part of their care?
Does CBG/CBD oil help reduce pain, numbness, or other symptoms of CIPN?
Participants will:
Take CBG/CBD oil under the tongue (sublingually) twice daily for 12 weeks
Complete regular symptom assessments and functional tests during study visits
Provide blood samples for cannabinoid and metabolite level testing